Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03401788
Title A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Age Groups: senior | adult
Covered Countries USA | GBR | FRA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
University of Pennsylvania Medical Center Philadelphia Pennsylvania 19104 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
Vanderbilt Medical Center Nashville Tennessee 37232 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
Aarhus University Hospital Aarhus Denmark Details
Hospital Georges Pompidou Paris France Details
Cambridge University Hospital Cambridge United Kingdom Details
*Shaded cells indicate that there was no data available from for the field